Context Therapeutics is trading 5.9% lower at $0.33, with no company-specific explanation identified for the September 28 move. - The latest located company update was September 9, announcing the first patient dosed in its Phase 1 CT-202 trial. - Reuters reported global stocks fell as Brent crude rose 4% to $108.5 a barrel amid stalled U.S.-Iran talks and inflation and rate concerns; this backdrop may weigh on sentiment but is not established as the direct cause.